Dsm Delivered 18% Higher EBITDA, While Facing a Challenging Economic Environment in 2013

Royal DSM, the Life Sciences and Materials Sciences company reported final, audited, results for 2013.  These results confirm the preliminary, unaudited results DSM published on 21 January 2014. DSM also issues its Integrated Annual Report, which can be found on DSM’s corporate website.

- 2013 FY EBITDA substantially up to €1,314 million (2012 FY: €1,109 million)
- Q4 2013 EBITDA €316 million (Q4 2012: €243 million)
- Strong cash generation from operating activities of €889 million in 2013 (2012: €730 million)
- Dividend increase of 10% proposed to €1.65 per ordinary share (2012: €1.50)
- Share repurchase program to hedge existing option plans continues
- Target for 2014 to improve business performance to at least offset negative currency impact

For the full year 2013, DSM delivered 18% higher EBITDA, while facing a challenging economic environment. For Q4 the company realized 30% higher EBITDA.

In Q4 all clusters delivered a solid performance despite negative exchange rate effects. Nutrition was in addition impacted by a combination of unrelated market headwinds.

These included weakness in dietary supplements and fish oil based Omega 3 markets in the US, soft demand in Western food & beverage markets, and price pressures especially in vitamin E following weak demand in animal feed markets earlier in the year.

DSM previously signaled these adverse conditions, but the impact through the end of the year was more pronounced than anticipated.